Synthorx
acquired by SanofiLa Jolla, US · Founded 2014 · 6 known investors
Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.
Biotech
Founders & leadership
JL
Jay LichterNamed on SEC filing
DD
Douglas DownsNamed on SEC filing
FR
Floyd RomesbergNamed on SEC filing
CT
Court TurnerNamed on SEC filing
Investors · 6
Reported raises · per SEC filings
Form D private placements$34.7M disclosed across 3 rounds · 2014–2018
▶$26.5MraisedApr 2018 · 10 investors · BiotechnologyRule 506(b)
▶$26.5MraisedApr 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay LichterDirector
- Floyd RomesbergDirector
- Peter ThompsonDirector
- Andrew LevinDirector
- Laura ShawverExecutive Officer, Director
- Offering amount
- $63.7M
- Amount sold
- $26.5M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$5MraisedJul 2016 · 5 investors · BiotechnologyRule 506(b)
▶$5MraisedJul 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Floyd RomesbergDirector
- Court TurnerExecutive Officer, Director
- Jay LichterDirector
- Andrew LevinDirector
- Tighe ReardonExecutive Officer
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$3.1MraisedJun 2014 · 3 investors · BiotechnologyRule 506(b)
▶$3.1MraisedJun 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay LichterDirector
- Douglas DownsExecutive Officer
- Floyd RomesbergDirector
- Court TurnerExecutive Officer, Director
- Offering amount
- $6.3M
- Amount sold
- $3.1M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Synthorx do?
- Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.
- Who are Synthorx's investors?
- Synthorx's investors include Avalon BioVentures, Boutique Venture Partners, Correlation Ventures, OUP (Osage University Partners), RA Capital, venBio Partners.
- How much funding has Synthorx raised?
- Synthorx has disclosed $34.7M raised across 3 rounds.
- Who acquired Synthorx?
- Synthorx was acquired by Sanofi.
- Where is Synthorx headquartered?
- Synthorx is headquartered in La Jolla, US.